DE3787020D1 - Herstellung von m-csf. - Google Patents

Herstellung von m-csf.

Info

Publication number
DE3787020D1
DE3787020D1 DE8787903104T DE3787020T DE3787020D1 DE 3787020 D1 DE3787020 D1 DE 3787020D1 DE 8787903104 T DE8787903104 T DE 8787903104T DE 3787020 T DE3787020 T DE 3787020T DE 3787020 D1 DE3787020 D1 DE 3787020D1
Authority
DE
Germany
Prior art keywords
production
csf
polypeptides
methods
provided via
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8787903104T
Other languages
English (en)
Other versions
DE3787020T2 (de
Inventor
Steven Clark
Gordon Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
Original Assignee
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/860,377 external-priority patent/US4879227A/en
Priority claimed from US06/940,362 external-priority patent/US4868119A/en
Application filed by Genetics Institute LLC filed Critical Genetics Institute LLC
Publication of DE3787020D1 publication Critical patent/DE3787020D1/de
Application granted granted Critical
Publication of DE3787020T2 publication Critical patent/DE3787020T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Prostheses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE87903104T 1986-05-06 1987-04-13 Herstellung von m-csf. Expired - Fee Related DE3787020T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/860,377 US4879227A (en) 1986-05-06 1986-05-06 Production of a recombinant human colony stimulating factor
US06/940,362 US4868119A (en) 1986-12-11 1986-12-11 Hematopoietic growth factors

Publications (2)

Publication Number Publication Date
DE3787020D1 true DE3787020D1 (de) 1993-09-16
DE3787020T2 DE3787020T2 (de) 1993-12-16

Family

ID=27127565

Family Applications (1)

Application Number Title Priority Date Filing Date
DE87903104T Expired - Fee Related DE3787020T2 (de) 1986-05-06 1987-04-13 Herstellung von m-csf.

Country Status (21)

Country Link
US (1) US5573763A (de)
EP (1) EP0307402B1 (de)
JP (2) JP2579981B2 (de)
KR (1) KR960004453B1 (de)
AT (1) ATE92966T1 (de)
AU (1) AU606056B2 (de)
CA (1) CA1334942C (de)
DE (1) DE3787020T2 (de)
DK (1) DK2688A (de)
ES (1) ES2007341A6 (de)
FI (1) FI884877A (de)
GR (1) GR870688B (de)
HU (1) HU212277B (de)
IE (1) IE60835B1 (de)
IL (1) IL82400A0 (de)
MX (1) MX9203130A (de)
MY (1) MY101209A (de)
NO (1) NO880022L (de)
OA (1) OA09112A (de)
PH (1) PH24301A (de)
WO (1) WO1987006954A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6146851A (en) * 1985-02-05 2000-11-14 Chiron Corporation DNA encoding NV2 (long form) and carboxy truncated fragments thereof
US4847201A (en) * 1985-02-05 1989-07-11 Cetus Corporation DNA encoding for CSF-1 and accompanying recombinant systems
US5556620A (en) * 1985-02-05 1996-09-17 Cetus Oncology Corporation Use of recombinant colony stimulating factor-1 to enhance wound healing
US6156300A (en) * 1985-02-05 2000-12-05 Chiron Corporation Point mutants of N∇2 CSF-1 and carboxy truncated fragments thereof
EP0209601B1 (de) * 1985-02-05 1993-12-15 Cetus Oncology Corporation Rekombinanter koloniestimulierender faktor-1
US5837229A (en) * 1985-02-05 1998-11-17 Chiron Corporation Uses of recombinant colony stimulating factor-1
US5104650A (en) * 1985-02-05 1992-04-14 Cetus Corporation Uses of recombinant colony stimulating factor-1
US5422105A (en) * 1985-02-05 1995-06-06 Cetus Oncology Corporation Use of recombinant colony stimulating factor 1
US5573930A (en) 1985-02-05 1996-11-12 Cetus Oncology Corporation DNA encoding various forms of colony stimulating factor-1
US4808611A (en) * 1986-07-30 1989-02-28 Immunex Corporation Use of interleukin-1 to induce development of multipotent hemopoietic cell populations
JP2583770B2 (ja) * 1986-09-17 1997-02-19 大塚製薬株式会社 遺伝子
JP2583829B2 (ja) * 1986-09-17 1997-02-19 大塚製薬株式会社 ヒトｍ−ｃｓｆ
US5650297A (en) * 1986-09-17 1997-07-22 Otsuka Pharmaceutical Co., Ltd. DNA encoding human colony-stimulating factors
JPH07100720B2 (ja) * 1987-07-17 1995-11-01 森永乳業株式会社 コロニー刺激因子の製造法
CA1339757C (en) 1987-04-16 1998-03-17 Robert F. Halenbeck Production of purified biologically active, bacterially produced recombinant human csf-1
IL86090A (en) * 1987-04-16 1993-03-15 Cetus Oncology Corp Production of purified, biologically active, bacterially produced recombinant human csf-1
US4929700A (en) * 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
EP0643972B1 (de) * 1987-09-22 2002-03-06 Chiron Corporation Verwendung von rekombinantem koloniestimulierendem Faktor-1 zur Herstellung eines Medikaments gegen Cytomegalovirusinfektionen
US5260421A (en) * 1987-12-21 1993-11-09 Applied Research Systems Ars Holding N.V. Site-directed mutagenesis modified glycoprotein hormones
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
DK54589A (da) * 1988-02-08 1989-08-09 Otsuka Pharma Co Ltd Humane kolonistmulerende faktorer
JPH0610137B2 (ja) * 1988-02-29 1994-02-09 新技術事業団 ヒト単球−マクロファージコロニー刺激因子を有効成分とする造血器疾患治療剤
KR900700156A (ko) * 1988-04-27 1990-08-11 원본미기재 개선된 방사선 치료법
US5888495A (en) * 1988-05-23 1999-03-30 Genetics Institute, Inc. Method of producing storage stable M-CSF lyophilizates
US5171675A (en) * 1988-07-28 1992-12-15 Cerretti Douglas P Macrophage colony stimulating factor-γ
JPH0651640B2 (ja) * 1989-01-30 1994-07-06 シェリング・コーポレーション Ｇｍ―ｃｓｆを用いる白血球機能障害の治療
DK0457804T3 (da) * 1989-02-10 1996-09-23 Chiron Corp M-CSF-monoklonale antistoffer, som genkender en neutraliserende, konformational epitop
AU625081B2 (en) * 1989-02-28 1992-07-02 Morinaga Milk Industry Company Limited Human monocyte-macrophage-csf preparations
US5288487A (en) * 1989-02-28 1994-02-22 Morinaga Milk Industry Co., Ltd. Human monocyte-macrophage-CSF preparations
AU5355790A (en) * 1989-04-19 1990-11-16 Cetus Corporation Multifunctional m-csf proteins and genes encoding therefor
DE69026440T2 (de) * 1989-07-27 1996-10-17 Denki Kagaku Kogyo Kk Für M-CSF kodierendes Gen und dazu gehörende rekombinante Systeme
WO1994016075A2 (en) * 1993-01-13 1994-07-21 Genetics Institute, Inc. Process for producing m-csf 223
ATE386811T1 (de) 1996-04-05 2008-03-15 Novartis Vaccines & Diagnostic Alphaviren-vektors mit eine reduzierte inhibierung der synthese von zellmakromolekülen
US6455678B1 (en) * 1996-04-26 2002-09-24 Amcell Corporation Human hematopoietic stem and progenitor cell antigen
ATE299030T1 (de) * 1996-07-10 2005-07-15 Meiji Dairies Corp Verwendung von proteinen aus der mk familie als hämatopoietischer faktor
WO2000018374A1 (en) * 1998-10-01 2000-04-06 Elan Pharma International, Ltd. Controlled release nanoparticulate compositions
US7108852B2 (en) * 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
EP2089049A4 (de) * 2006-11-17 2011-11-16 Biogen Idec Inc Systemische verabreichung kolonienstimulierender faktoren zur behandlung von amyloid-assoziierten erkrankungen
WO2024017998A1 (en) 2022-07-21 2024-01-25 Technische Universität Dresden M-csf for use in the prophylaxis and/or treatment of viral infections in states of immunosuppression
EP4309666A1 (de) 2022-07-21 2024-01-24 Technische Universität Dresden M-csf zur verwendung bei der prophylaxe und/oder behandlung viraler infektionen bei immunsuppressionszuständen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4784949A (en) * 1984-04-19 1988-11-15 Cetus Corporation Universal dominant selectable marker cassette
EP0211899B1 (de) * 1985-02-05 1992-09-23 Cetus Oncology Corporation Reinigung des natürlichen kolonie-stimulierenden faktors-1
EP0209601B1 (de) * 1985-02-05 1993-12-15 Cetus Oncology Corporation Rekombinanter koloniestimulierender faktor-1
US4847201A (en) * 1985-02-05 1989-07-11 Cetus Corporation DNA encoding for CSF-1 and accompanying recombinant systems
JP2583770B2 (ja) * 1986-09-17 1997-02-19 大塚製薬株式会社 遺伝子
JP2644794B2 (ja) * 1986-10-24 1997-08-25 カイロン コーポレイション 新規な型のコロニー刺激因子―１

Also Published As

Publication number Publication date
DK2688D0 (da) 1988-01-05
DK2688A (da) 1988-03-07
IL82400A0 (en) 1987-11-30
DE3787020T2 (de) 1993-12-16
IE870994L (en) 1987-11-06
JPH01502397A (ja) 1989-08-24
FI884877A0 (fi) 1988-10-21
GR870688B (en) 1987-09-07
WO1987006954A1 (en) 1987-11-19
OA09112A (en) 1991-10-31
HU212277B (en) 1996-04-29
FI884877A (fi) 1988-10-21
JP2579981B2 (ja) 1997-02-12
AU606056B2 (en) 1991-01-31
NO880022D0 (no) 1988-01-05
US5573763A (en) 1996-11-12
MX9203130A (es) 1992-07-01
EP0307402A4 (de) 1990-02-22
ES2007341A6 (es) 1989-06-16
NO880022L (no) 1988-01-05
AU7289087A (en) 1987-12-01
EP0307402A1 (de) 1989-03-22
PH24301A (en) 1990-05-29
ATE92966T1 (de) 1993-08-15
KR960004453B1 (en) 1996-04-06
HUT47979A (en) 1989-04-28
CA1334942C (en) 1995-03-28
JPH07147989A (ja) 1995-06-13
IE60835B1 (en) 1994-08-24
KR880701288A (ko) 1988-07-26
MY101209A (en) 1991-08-17
EP0307402B1 (de) 1993-08-11

Similar Documents

Publication Publication Date Title
DE3787020D1 (de) Herstellung von m-csf.
DE69023948T2 (de) Herstellung von peroxidhaltigen Perfluorpolyethern.
DE3780933D1 (de) Herstellung von aminoalanen.
NO881073D0 (no) En ny familie primate hematopoietiske vekstfaktorer.
DE3583940D1 (de) Herstellung von streptavidinaehnlichen polypeptiden.
NO854435L (no) Fremgangsmaate for fremstilling av polypeptider.
DE3770889D1 (de) Herstellung von kubischem bornitrid.
DE68914992D1 (de) Herstellung von durch nitratoalkyl substituierten cyclischen äthern.
DE3767399D1 (de) Herstellung und verpacken von struempfen.
DE69004199T2 (de) Herstellung von Cymenol durch direkte Dehydrogenierung.
PT85602A (en) Oxolabdanes a process for their preparation and their use as medicaments
DE3766873D1 (de) Herstellung von substituierten dichlormethylpyridinen.
DE3773666D1 (de) Herstellung von n-epoxypropyl-lactamen.
DE3676116D1 (de) Herstellung von azetidin-derivaten.
DE3773219D1 (de) Herstellung von tetrachlorpyridin.
DE3675948D1 (de) Herstellung von alkyltrifluoracetoacetat.
DE3780573D1 (de) Herstellung von teilweise stabilisiertem tetragonalem zirkondioxid.
ATE96415T1 (de) Herstellung von cymenol durch direkte dehydrogenierung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: GENETICS INSTITUTE, LLC, CAMBRIDGE, MASS., US

8339 Ceased/non-payment of the annual fee